ArticleAntimicrobial agents and chemotherapy2004
Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 99 citations in OpenAlex.
- Endoscopic sinus surgery reduces antibiotic utilization in rhinosinusitis.International forum of allergy & rhinologyTrial
- Montelukast treatsMicrobiology spectrum · 2025Article
- The effects of daptomycin on cell wall biosynthesis in Enterococcal faecalis.Scientific reports · 2023Article
- Amoxicillin-resistanteLife · 2022Article
- Antimicrobial resistance genes are enriched in aerosols near impacted urban surface waters in La Paz, Bolivia.Environmental research · 2021Article
- Allogenous Selection of Mutational Collateral Resistance: Old Drugs Select for New Resistance Within Antibiotic Families.Frontiers in microbiology · 2021Review
- Host population structure and treatment frequency maintain balancing selection on drug resistance.Journal of the Royal Society, Interface · 2017Article
- CRH Affects the Phenotypic Expression of Sepsis-Associated Virulence Factors byFrontiers in cellular and infection microbiology · 2017Article
- Collateral Damage: Detrimental Effect of Antibiotics on the Development of Protective Immune Memory.mBio · 2016Review
- Solid-state NMR characterization of amphomycin effects on peptidoglycan and wall teichoic acid biosyntheses in Staphylococcus aureus.Scientific reports · 2016Article
- Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.Clinical microbiology reviews · 2016Review
- Transcriptome analysis of Streptococcus pneumoniae treated with the designed antimicrobial peptides, DM3.Scientific reports · 2016Article
- From knock-out phenotype to three-dimensional structure of a promising antibiotic target from Streptococcus pneumoniae.PloS one · 2013Article
- Bacteremic pneumonia caused by extensively drug-resistant Streptococcus pneumoniae.Journal of clinical microbiology · 2012Article
- Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008.Antimicrobial agents and chemotherapy · 2012Article
- Impact of penicillin nonsusceptibility on clinical outcomes of patients with nonmeningeal Streptococcus pneumoniae bacteremia in the era of the 2008 clinical and laboratory standards institute penicillin breakpoints.Antimicrobial agents and chemotherapy · 2012Article
- Emergence of a unique penicillin-resistant Streptococcus pneumoniae serogroup 35 strain.Journal of clinical microbiology · 2011Article
- In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.Antimicrobial agents and chemotherapy · 2009Article
- Pneumonia and other respiratory infections.Pediatric clinics of North America · 2009Review
- In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.Antimicrobial agents and chemotherapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Penicillin resistance threatens the treatment of pneumococcal infections. We used sentinel hospital surveillance (1978 to 2001) and population-based surveillance (1995 to 2001) in seven states in the Active Bacterial Core surveillance of the Emerging Infections Program Network to document the emergence in the United States of invasive pneumococcal isolates with very-high-level penicillin resistance (MIC > or = 8 microg/ml). Very-high-level penicillin resistance was first detected in 1995 in multiple pneumococcal serotypes in three regions of the United States. The prevalence increased from 0.56% (14 of 2,507) of isolates in 1995 to 0.87% in 2001 (P = 0.03), with peaks in 1996 and 2000 associated with epidemics in Georgia and Maryland. For a majority of the strains the MICs of amoxicillin (91%), cefuroxime (100%), and cefotaxime (68%), were > or =8 microg/ml and all were resistant to at least one other drug class. Pneumonia (50%) and bacteremia (36%) were the most common clinical presentations. Factors associated with very highly resistant infections included residence in Tennessee, age of <5 or > or =65 years, and resistance to at least three drug classes. Hospitalization and case fatality rates were not higher than those of other pneumococcal infection patients; length of hospital stay was longer, controlling for age. Among the strains from 2000 and 2001, 39% were related to Tennessee(23F)-4 and 35% were related to England(14-)9. After the introduction of the pneumococcal conjugate vaccine, the incidence of highly penicillin resistant infections decreased by 50% among children <5 years of age. The emergence, clonality, and association of very-high-level penicillin resistance with multiple drug resistance requires further monitoring and highlights the need for novel agents active against the pneumococcus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.